Global Duchenne Muscular Dystrophy Drugs Market Growth (Status and Outlook) 2024-2030
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Duchenne Muscular Dystrophy Drugs market size is projected to grow from US$ 989.8 million in 2023 to US$ 8185.6 million in 2030; it is expected to grow at a CAGR of 35.2% from 2024 to 2030.
LPI (LP Information)' newest research report, the “Duchenne Muscular Dystrophy Drugs Industry Forecast” looks at past sales and reviews total world Duchenne Muscular Dystrophy Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Duchenne Muscular Dystrophy Drugs sales for 2024 through 2030. With Duchenne Muscular Dystrophy Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Duchenne Muscular Dystrophy Drugs industry.
This Insight Report provides a comprehensive analysis of the global Duchenne Muscular Dystrophy Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Duchenne Muscular Dystrophy Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Duchenne Muscular Dystrophy Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Duchenne Muscular Dystrophy Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Duchenne Muscular Dystrophy Drugs.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of Duchenne Muscular Dystrophy Drugs market by product type, application, key players and key regions and countries.
Segmentation by type
The global Duchenne Muscular Dystrophy Drugs market size is projected to grow from US$ 989.8 million in 2023 to US$ 8185.6 million in 2030; it is expected to grow at a CAGR of 35.2% from 2024 to 2030.
LPI (LP Information)' newest research report, the “Duchenne Muscular Dystrophy Drugs Industry Forecast” looks at past sales and reviews total world Duchenne Muscular Dystrophy Drugs sales in 2023, providing a comprehensive analysis by region and market sector of projected Duchenne Muscular Dystrophy Drugs sales for 2024 through 2030. With Duchenne Muscular Dystrophy Drugs sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Duchenne Muscular Dystrophy Drugs industry.
This Insight Report provides a comprehensive analysis of the global Duchenne Muscular Dystrophy Drugs landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Duchenne Muscular Dystrophy Drugs portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Duchenne Muscular Dystrophy Drugs market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Duchenne Muscular Dystrophy Drugs and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Duchenne Muscular Dystrophy Drugs.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report presents a comprehensive overview, market shares, and growth opportunities of Duchenne Muscular Dystrophy Drugs market by product type, application, key players and key regions and countries.
Segmentation by type
- Molecular-based Therapies
- Steroid Therapy
- Other
- Hospitals
- Clinics
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Biogen
- Roche
- Daiichi Sankyo
- Pfizer
- Cumberland Pharmaceuticals
- Santhera Pharmaceuticals
- Taiho Pharmaceutical
- Teijin Pharma
- Akashi Therapeutics
- Sarepta Therapeutics
- BioMarin
- Fibrogen Inc
- Nobelpharma Co. Ltd
- Eloxx Pharmaceuticals
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Duchenne Muscular Dystrophy Drugs Market Size 2019-2030
2.1.2 Duchenne Muscular Dystrophy Drugs Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Duchenne Muscular Dystrophy Drugs Segment by Type
2.2.1 Molecular-based Therapies
2.2.2 Steroid Therapy
2.2.3 Other
2.3 Duchenne Muscular Dystrophy Drugs Market Size by Type
2.3.1 Duchenne Muscular Dystrophy Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
2.4 Duchenne Muscular Dystrophy Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Others
2.5 Duchenne Muscular Dystrophy Drugs Market Size by Application
2.5.1 Duchenne Muscular Dystrophy Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2019-2024)
3 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE BY PLAYER
3.1 Duchenne Muscular Dystrophy Drugs Market Size Market Share by Players
3.1.1 Global Duchenne Muscular Dystrophy Drugs Revenue by Players (2019-2024)
3.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Duchenne Muscular Dystrophy Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 DUCHENNE MUSCULAR DYSTROPHY DRUGS BY REGIONS
4.1 Duchenne Muscular Dystrophy Drugs Market Size by Regions (2019-2024)
4.2 Americas Duchenne Muscular Dystrophy Drugs Market Size Growth (2019-2024)
4.3 APAC Duchenne Muscular Dystrophy Drugs Market Size Growth (2019-2024)
4.4 Europe Duchenne Muscular Dystrophy Drugs Market Size Growth (2019-2024)
4.5 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Duchenne Muscular Dystrophy Drugs Market Size by Country (2019-2024)
5.2 Americas Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024)
5.3 Americas Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Duchenne Muscular Dystrophy Drugs Market Size by Region (2019-2024)
6.2 APAC Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024)
6.3 APAC Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Duchenne Muscular Dystrophy Drugs by Country (2019-2024)
7.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024)
7.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs by Region (2019-2024)
8.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024)
8.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET FORECAST
10.1 Global Duchenne Muscular Dystrophy Drugs Forecast by Regions (2025-2030)
10.1.1 Global Duchenne Muscular Dystrophy Drugs Forecast by Regions (2025-2030)
10.1.2 Americas Duchenne Muscular Dystrophy Drugs Forecast
10.1.3 APAC Duchenne Muscular Dystrophy Drugs Forecast
10.1.4 Europe Duchenne Muscular Dystrophy Drugs Forecast
10.1.5 Middle East & Africa Duchenne Muscular Dystrophy Drugs Forecast
10.2 Americas Duchenne Muscular Dystrophy Drugs Forecast by Country (2025-2030)
10.2.1 United States Duchenne Muscular Dystrophy Drugs Market Forecast
10.2.2 Canada Duchenne Muscular Dystrophy Drugs Market Forecast
10.2.3 Mexico Duchenne Muscular Dystrophy Drugs Market Forecast
10.2.4 Brazil Duchenne Muscular Dystrophy Drugs Market Forecast
10.3 APAC Duchenne Muscular Dystrophy Drugs Forecast by Region (2025-2030)
10.3.1 China Duchenne Muscular Dystrophy Drugs Market Forecast
10.3.2 Japan Duchenne Muscular Dystrophy Drugs Market Forecast
10.3.3 Korea Duchenne Muscular Dystrophy Drugs Market Forecast
10.3.4 Southeast Asia Duchenne Muscular Dystrophy Drugs Market Forecast
10.3.5 India Duchenne Muscular Dystrophy Drugs Market Forecast
10.3.6 Australia Duchenne Muscular Dystrophy Drugs Market Forecast
10.4 Europe Duchenne Muscular Dystrophy Drugs Forecast by Country (2025-2030)
10.4.1 Germany Duchenne Muscular Dystrophy Drugs Market Forecast
10.4.2 France Duchenne Muscular Dystrophy Drugs Market Forecast
10.4.3 UK Duchenne Muscular Dystrophy Drugs Market Forecast
10.4.4 Italy Duchenne Muscular Dystrophy Drugs Market Forecast
10.4.5 Russia Duchenne Muscular Dystrophy Drugs Market Forecast
10.5 Middle East & Africa Duchenne Muscular Dystrophy Drugs Forecast by Region (2025-2030)
10.5.1 Egypt Duchenne Muscular Dystrophy Drugs Market Forecast
10.5.2 South Africa Duchenne Muscular Dystrophy Drugs Market Forecast
10.5.3 Israel Duchenne Muscular Dystrophy Drugs Market Forecast
10.5.4 Turkey Duchenne Muscular Dystrophy Drugs Market Forecast
10.5.5 GCC Countries Duchenne Muscular Dystrophy Drugs Market Forecast
10.6 Global Duchenne Muscular Dystrophy Drugs Forecast by Type (2025-2030)
10.7 Global Duchenne Muscular Dystrophy Drugs Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 Biogen
11.1.1 Biogen Company Information
11.1.2 Biogen Duchenne Muscular Dystrophy Drugs Product Offered
11.1.3 Biogen Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Biogen Main Business Overview
11.1.5 Biogen Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Duchenne Muscular Dystrophy Drugs Product Offered
11.2.3 Roche Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 Daiichi Sankyo
11.3.1 Daiichi Sankyo Company Information
11.3.2 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product Offered
11.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Daiichi Sankyo Main Business Overview
11.3.5 Daiichi Sankyo Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Duchenne Muscular Dystrophy Drugs Product Offered
11.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 Cumberland Pharmaceuticals
11.5.1 Cumberland Pharmaceuticals Company Information
11.5.2 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offered
11.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Cumberland Pharmaceuticals Main Business Overview
11.5.5 Cumberland Pharmaceuticals Latest Developments
11.6 Santhera Pharmaceuticals
11.6.1 Santhera Pharmaceuticals Company Information
11.6.2 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offered
11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Santhera Pharmaceuticals Main Business Overview
11.6.5 Santhera Pharmaceuticals Latest Developments
11.7 Taiho Pharmaceutical
11.7.1 Taiho Pharmaceutical Company Information
11.7.2 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product Offered
11.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Taiho Pharmaceutical Main Business Overview
11.7.5 Taiho Pharmaceutical Latest Developments
11.8 Teijin Pharma
11.8.1 Teijin Pharma Company Information
11.8.2 Teijin Pharma Duchenne Muscular Dystrophy Drugs Product Offered
11.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Teijin Pharma Main Business Overview
11.8.5 Teijin Pharma Latest Developments
11.9 Akashi Therapeutics
11.9.1 Akashi Therapeutics Company Information
11.9.2 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product Offered
11.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Akashi Therapeutics Main Business Overview
11.9.5 Akashi Therapeutics Latest Developments
11.10 Sarepta Therapeutics
11.10.1 Sarepta Therapeutics Company Information
11.10.2 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product Offered
11.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Sarepta Therapeutics Main Business Overview
11.10.5 Sarepta Therapeutics Latest Developments
11.11 BioMarin
11.11.1 BioMarin Company Information
11.11.2 BioMarin Duchenne Muscular Dystrophy Drugs Product Offered
11.11.3 BioMarin Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 BioMarin Main Business Overview
11.11.5 BioMarin Latest Developments
11.12 Fibrogen Inc
11.12.1 Fibrogen Inc Company Information
11.12.2 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product Offered
11.12.3 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Fibrogen Inc Main Business Overview
11.12.5 Fibrogen Inc Latest Developments
11.13 Nobelpharma Co. Ltd
11.13.1 Nobelpharma Co. Ltd Company Information
11.13.2 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product Offered
11.13.3 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Nobelpharma Co. Ltd Main Business Overview
11.13.5 Nobelpharma Co. Ltd Latest Developments
11.14 Eloxx Pharmaceuticals
11.14.1 Eloxx Pharmaceuticals Company Information
11.14.2 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offered
11.14.3 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Eloxx Pharmaceuticals Main Business Overview
11.14.5 Eloxx Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Duchenne Muscular Dystrophy Drugs Market Size 2019-2030
2.1.2 Duchenne Muscular Dystrophy Drugs Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Duchenne Muscular Dystrophy Drugs Segment by Type
2.2.1 Molecular-based Therapies
2.2.2 Steroid Therapy
2.2.3 Other
2.3 Duchenne Muscular Dystrophy Drugs Market Size by Type
2.3.1 Duchenne Muscular Dystrophy Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
2.4 Duchenne Muscular Dystrophy Drugs Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Others
2.5 Duchenne Muscular Dystrophy Drugs Market Size by Application
2.5.1 Duchenne Muscular Dystrophy Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2019-2024)
3 DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET SIZE BY PLAYER
3.1 Duchenne Muscular Dystrophy Drugs Market Size Market Share by Players
3.1.1 Global Duchenne Muscular Dystrophy Drugs Revenue by Players (2019-2024)
3.1.2 Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Duchenne Muscular Dystrophy Drugs Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 DUCHENNE MUSCULAR DYSTROPHY DRUGS BY REGIONS
4.1 Duchenne Muscular Dystrophy Drugs Market Size by Regions (2019-2024)
4.2 Americas Duchenne Muscular Dystrophy Drugs Market Size Growth (2019-2024)
4.3 APAC Duchenne Muscular Dystrophy Drugs Market Size Growth (2019-2024)
4.4 Europe Duchenne Muscular Dystrophy Drugs Market Size Growth (2019-2024)
4.5 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size Growth (2019-2024)
5 AMERICAS
5.1 Americas Duchenne Muscular Dystrophy Drugs Market Size by Country (2019-2024)
5.2 Americas Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024)
5.3 Americas Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Duchenne Muscular Dystrophy Drugs Market Size by Region (2019-2024)
6.2 APAC Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024)
6.3 APAC Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Duchenne Muscular Dystrophy Drugs by Country (2019-2024)
7.2 Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024)
7.3 Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Duchenne Muscular Dystrophy Drugs by Region (2019-2024)
8.2 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024)
8.3 Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL DUCHENNE MUSCULAR DYSTROPHY DRUGS MARKET FORECAST
10.1 Global Duchenne Muscular Dystrophy Drugs Forecast by Regions (2025-2030)
10.1.1 Global Duchenne Muscular Dystrophy Drugs Forecast by Regions (2025-2030)
10.1.2 Americas Duchenne Muscular Dystrophy Drugs Forecast
10.1.3 APAC Duchenne Muscular Dystrophy Drugs Forecast
10.1.4 Europe Duchenne Muscular Dystrophy Drugs Forecast
10.1.5 Middle East & Africa Duchenne Muscular Dystrophy Drugs Forecast
10.2 Americas Duchenne Muscular Dystrophy Drugs Forecast by Country (2025-2030)
10.2.1 United States Duchenne Muscular Dystrophy Drugs Market Forecast
10.2.2 Canada Duchenne Muscular Dystrophy Drugs Market Forecast
10.2.3 Mexico Duchenne Muscular Dystrophy Drugs Market Forecast
10.2.4 Brazil Duchenne Muscular Dystrophy Drugs Market Forecast
10.3 APAC Duchenne Muscular Dystrophy Drugs Forecast by Region (2025-2030)
10.3.1 China Duchenne Muscular Dystrophy Drugs Market Forecast
10.3.2 Japan Duchenne Muscular Dystrophy Drugs Market Forecast
10.3.3 Korea Duchenne Muscular Dystrophy Drugs Market Forecast
10.3.4 Southeast Asia Duchenne Muscular Dystrophy Drugs Market Forecast
10.3.5 India Duchenne Muscular Dystrophy Drugs Market Forecast
10.3.6 Australia Duchenne Muscular Dystrophy Drugs Market Forecast
10.4 Europe Duchenne Muscular Dystrophy Drugs Forecast by Country (2025-2030)
10.4.1 Germany Duchenne Muscular Dystrophy Drugs Market Forecast
10.4.2 France Duchenne Muscular Dystrophy Drugs Market Forecast
10.4.3 UK Duchenne Muscular Dystrophy Drugs Market Forecast
10.4.4 Italy Duchenne Muscular Dystrophy Drugs Market Forecast
10.4.5 Russia Duchenne Muscular Dystrophy Drugs Market Forecast
10.5 Middle East & Africa Duchenne Muscular Dystrophy Drugs Forecast by Region (2025-2030)
10.5.1 Egypt Duchenne Muscular Dystrophy Drugs Market Forecast
10.5.2 South Africa Duchenne Muscular Dystrophy Drugs Market Forecast
10.5.3 Israel Duchenne Muscular Dystrophy Drugs Market Forecast
10.5.4 Turkey Duchenne Muscular Dystrophy Drugs Market Forecast
10.5.5 GCC Countries Duchenne Muscular Dystrophy Drugs Market Forecast
10.6 Global Duchenne Muscular Dystrophy Drugs Forecast by Type (2025-2030)
10.7 Global Duchenne Muscular Dystrophy Drugs Forecast by Application (2025-2030)
11 KEY PLAYERS ANALYSIS
11.1 Biogen
11.1.1 Biogen Company Information
11.1.2 Biogen Duchenne Muscular Dystrophy Drugs Product Offered
11.1.3 Biogen Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Biogen Main Business Overview
11.1.5 Biogen Latest Developments
11.2 Roche
11.2.1 Roche Company Information
11.2.2 Roche Duchenne Muscular Dystrophy Drugs Product Offered
11.2.3 Roche Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Roche Main Business Overview
11.2.5 Roche Latest Developments
11.3 Daiichi Sankyo
11.3.1 Daiichi Sankyo Company Information
11.3.2 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product Offered
11.3.3 Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Daiichi Sankyo Main Business Overview
11.3.5 Daiichi Sankyo Latest Developments
11.4 Pfizer
11.4.1 Pfizer Company Information
11.4.2 Pfizer Duchenne Muscular Dystrophy Drugs Product Offered
11.4.3 Pfizer Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Pfizer Main Business Overview
11.4.5 Pfizer Latest Developments
11.5 Cumberland Pharmaceuticals
11.5.1 Cumberland Pharmaceuticals Company Information
11.5.2 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offered
11.5.3 Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Cumberland Pharmaceuticals Main Business Overview
11.5.5 Cumberland Pharmaceuticals Latest Developments
11.6 Santhera Pharmaceuticals
11.6.1 Santhera Pharmaceuticals Company Information
11.6.2 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offered
11.6.3 Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Santhera Pharmaceuticals Main Business Overview
11.6.5 Santhera Pharmaceuticals Latest Developments
11.7 Taiho Pharmaceutical
11.7.1 Taiho Pharmaceutical Company Information
11.7.2 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product Offered
11.7.3 Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Taiho Pharmaceutical Main Business Overview
11.7.5 Taiho Pharmaceutical Latest Developments
11.8 Teijin Pharma
11.8.1 Teijin Pharma Company Information
11.8.2 Teijin Pharma Duchenne Muscular Dystrophy Drugs Product Offered
11.8.3 Teijin Pharma Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Teijin Pharma Main Business Overview
11.8.5 Teijin Pharma Latest Developments
11.9 Akashi Therapeutics
11.9.1 Akashi Therapeutics Company Information
11.9.2 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product Offered
11.9.3 Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Akashi Therapeutics Main Business Overview
11.9.5 Akashi Therapeutics Latest Developments
11.10 Sarepta Therapeutics
11.10.1 Sarepta Therapeutics Company Information
11.10.2 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product Offered
11.10.3 Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Sarepta Therapeutics Main Business Overview
11.10.5 Sarepta Therapeutics Latest Developments
11.11 BioMarin
11.11.1 BioMarin Company Information
11.11.2 BioMarin Duchenne Muscular Dystrophy Drugs Product Offered
11.11.3 BioMarin Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 BioMarin Main Business Overview
11.11.5 BioMarin Latest Developments
11.12 Fibrogen Inc
11.12.1 Fibrogen Inc Company Information
11.12.2 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product Offered
11.12.3 Fibrogen Inc Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.12.4 Fibrogen Inc Main Business Overview
11.12.5 Fibrogen Inc Latest Developments
11.13 Nobelpharma Co. Ltd
11.13.1 Nobelpharma Co. Ltd Company Information
11.13.2 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product Offered
11.13.3 Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.13.4 Nobelpharma Co. Ltd Main Business Overview
11.13.5 Nobelpharma Co. Ltd Latest Developments
11.14 Eloxx Pharmaceuticals
11.14.1 Eloxx Pharmaceuticals Company Information
11.14.2 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offered
11.14.3 Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue, Gross Margin and Market Share (2019-2024)
11.14.4 Eloxx Pharmaceuticals Main Business Overview
11.14.5 Eloxx Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Duchenne Muscular Dystrophy Drugs Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Molecular-based Therapies
Table 3. Major Players of Steroid Therapy
Table 4. Major Players of Other
Table 5. Duchenne Muscular Dystrophy Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 6. Global Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024) & ($ Millions)
Table 7. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
Table 8. Duchenne Muscular Dystrophy Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 9. Global Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024) & ($ Millions)
Table 10. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2019-2024)
Table 11. Global Duchenne Muscular Dystrophy Drugs Revenue by Players (2019-2024) & ($ Millions)
Table 12. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Player (2019-2024)
Table 13. Duchenne Muscular Dystrophy Drugs Key Players Head office and Products Offered
Table 14. Duchenne Muscular Dystrophy Drugs Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Duchenne Muscular Dystrophy Drugs Market Size by Regions 2019-2024 & ($ Millions)
Table 18. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Regions (2019-2024)
Table 19. Global Duchenne Muscular Dystrophy Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 20. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Country/Region (2019-2024)
Table 21. Americas Duchenne Muscular Dystrophy Drugs Market Size by Country (2019-2024) & ($ Millions)
Table 22. Americas Duchenne Muscular Dystrophy Drugs Market Size Market Share by Country (2019-2024)
Table 23. Americas Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024) & ($ Millions)
Table 24. Americas Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
Table 25. Americas Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024) & ($ Millions)
Table 26. Americas Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2019-2024)
Table 27. APAC Duchenne Muscular Dystrophy Drugs Market Size by Region (2019-2024) & ($ Millions)
Table 28. APAC Duchenne Muscular Dystrophy Drugs Market Size Market Share by Region (2019-2024)
Table 29. APAC Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024) & ($ Millions)
Table 30. APAC Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
Table 31. APAC Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024) & ($ Millions)
Table 32. APAC Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2019-2024)
Table 33. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2019-2024) & ($ Millions)
Table 34. Europe Duchenne Muscular Dystrophy Drugs Market Size Market Share by Country (2019-2024)
Table 35. Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024) & ($ Millions)
Table 36. Europe Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
Table 37. Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024) & ($ Millions)
Table 38. Europe Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2019-2024)
Table 39. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Region (2019-2024) & ($ Millions)
Table 40. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size Market Share by Region (2019-2024)
Table 41. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024) & ($ Millions)
Table 42. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
Table 43. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024) & ($ Millions)
Table 44. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2019-2024)
Table 45. Key Market Drivers & Growth Opportunities of Duchenne Muscular Dystrophy Drugs
Table 46. Key Market Challenges & Risks of Duchenne Muscular Dystrophy Drugs
Table 47. Key Industry Trends of Duchenne Muscular Dystrophy Drugs
Table 48. Global Duchenne Muscular Dystrophy Drugs Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 49. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share Forecast by Regions (2025-2030)
Table 50. Global Duchenne Muscular Dystrophy Drugs Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 51. Global Duchenne Muscular Dystrophy Drugs Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 52. Biogen Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 53. Biogen Duchenne Muscular Dystrophy Drugs Product Offered
Table 54. Biogen Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 55. Biogen Main Business
Table 56. Biogen Latest Developments
Table 57. Roche Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 58. Roche Duchenne Muscular Dystrophy Drugs Product Offered
Table 59. Roche Main Business
Table 60. Roche Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 61. Roche Latest Developments
Table 62. Daiichi Sankyo Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 63. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product Offered
Table 64. Daiichi Sankyo Main Business
Table 65. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 66. Daiichi Sankyo Latest Developments
Table 67. Pfizer Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 68. Pfizer Duchenne Muscular Dystrophy Drugs Product Offered
Table 69. Pfizer Main Business
Table 70. Pfizer Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 71. Pfizer Latest Developments
Table 72. Cumberland Pharmaceuticals Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 73. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offered
Table 74. Cumberland Pharmaceuticals Main Business
Table 75. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 76. Cumberland Pharmaceuticals Latest Developments
Table 77. Santhera Pharmaceuticals Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 78. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offered
Table 79. Santhera Pharmaceuticals Main Business
Table 80. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 81. Santhera Pharmaceuticals Latest Developments
Table 82. Taiho Pharmaceutical Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 83. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product Offered
Table 84. Taiho Pharmaceutical Main Business
Table 85. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 86. Taiho Pharmaceutical Latest Developments
Table 87. Teijin Pharma Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 88. Teijin Pharma Duchenne Muscular Dystrophy Drugs Product Offered
Table 89. Teijin Pharma Main Business
Table 90. Teijin Pharma Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 91. Teijin Pharma Latest Developments
Table 92. Akashi Therapeutics Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 93. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product Offered
Table 94. Akashi Therapeutics Main Business
Table 95. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 96. Akashi Therapeutics Latest Developments
Table 97. Sarepta Therapeutics Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 98. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product Offered
Table 99. Sarepta Therapeutics Main Business
Table 100. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 101. Sarepta Therapeutics Latest Developments
Table 102. BioMarin Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 103. BioMarin Duchenne Muscular Dystrophy Drugs Product Offered
Table 104. BioMarin Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 105. BioMarin Main Business
Table 106. BioMarin Latest Developments
Table 107. Fibrogen Inc Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 108. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product Offered
Table 109. Fibrogen Inc Main Business
Table 110. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 111. Fibrogen Inc Latest Developments
Table 112. Nobelpharma Co. Ltd Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 113. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product Offered
Table 114. Nobelpharma Co. Ltd Main Business
Table 115. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 116. Nobelpharma Co. Ltd Latest Developments
Table 117. Eloxx Pharmaceuticals Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 118. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offered
Table 119. Eloxx Pharmaceuticals Main Business
Table 120. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 121. Eloxx Pharmaceuticals Latest Developments
Table 1. Duchenne Muscular Dystrophy Drugs Market Size CAGR by Region (2019 VS 2023 VS 2030) & ($ Millions)
Table 2. Major Players of Molecular-based Therapies
Table 3. Major Players of Steroid Therapy
Table 4. Major Players of Other
Table 5. Duchenne Muscular Dystrophy Drugs Market Size CAGR by Type (2019 VS 2023 VS 2030) & ($ Millions)
Table 6. Global Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024) & ($ Millions)
Table 7. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
Table 8. Duchenne Muscular Dystrophy Drugs Market Size CAGR by Application (2019 VS 2023 VS 2030) & ($ Millions)
Table 9. Global Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024) & ($ Millions)
Table 10. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2019-2024)
Table 11. Global Duchenne Muscular Dystrophy Drugs Revenue by Players (2019-2024) & ($ Millions)
Table 12. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Player (2019-2024)
Table 13. Duchenne Muscular Dystrophy Drugs Key Players Head office and Products Offered
Table 14. Duchenne Muscular Dystrophy Drugs Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Duchenne Muscular Dystrophy Drugs Market Size by Regions 2019-2024 & ($ Millions)
Table 18. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Regions (2019-2024)
Table 19. Global Duchenne Muscular Dystrophy Drugs Revenue by Country/Region (2019-2024) & ($ millions)
Table 20. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Country/Region (2019-2024)
Table 21. Americas Duchenne Muscular Dystrophy Drugs Market Size by Country (2019-2024) & ($ Millions)
Table 22. Americas Duchenne Muscular Dystrophy Drugs Market Size Market Share by Country (2019-2024)
Table 23. Americas Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024) & ($ Millions)
Table 24. Americas Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
Table 25. Americas Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024) & ($ Millions)
Table 26. Americas Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2019-2024)
Table 27. APAC Duchenne Muscular Dystrophy Drugs Market Size by Region (2019-2024) & ($ Millions)
Table 28. APAC Duchenne Muscular Dystrophy Drugs Market Size Market Share by Region (2019-2024)
Table 29. APAC Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024) & ($ Millions)
Table 30. APAC Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
Table 31. APAC Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024) & ($ Millions)
Table 32. APAC Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2019-2024)
Table 33. Europe Duchenne Muscular Dystrophy Drugs Market Size by Country (2019-2024) & ($ Millions)
Table 34. Europe Duchenne Muscular Dystrophy Drugs Market Size Market Share by Country (2019-2024)
Table 35. Europe Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024) & ($ Millions)
Table 36. Europe Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
Table 37. Europe Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024) & ($ Millions)
Table 38. Europe Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2019-2024)
Table 39. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Region (2019-2024) & ($ Millions)
Table 40. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size Market Share by Region (2019-2024)
Table 41. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Type (2019-2024) & ($ Millions)
Table 42. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
Table 43. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size by Application (2019-2024) & ($ Millions)
Table 44. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2019-2024)
Table 45. Key Market Drivers & Growth Opportunities of Duchenne Muscular Dystrophy Drugs
Table 46. Key Market Challenges & Risks of Duchenne Muscular Dystrophy Drugs
Table 47. Key Industry Trends of Duchenne Muscular Dystrophy Drugs
Table 48. Global Duchenne Muscular Dystrophy Drugs Market Size Forecast by Regions (2025-2030) & ($ Millions)
Table 49. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share Forecast by Regions (2025-2030)
Table 50. Global Duchenne Muscular Dystrophy Drugs Market Size Forecast by Type (2025-2030) & ($ Millions)
Table 51. Global Duchenne Muscular Dystrophy Drugs Market Size Forecast by Application (2025-2030) & ($ Millions)
Table 52. Biogen Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 53. Biogen Duchenne Muscular Dystrophy Drugs Product Offered
Table 54. Biogen Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 55. Biogen Main Business
Table 56. Biogen Latest Developments
Table 57. Roche Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 58. Roche Duchenne Muscular Dystrophy Drugs Product Offered
Table 59. Roche Main Business
Table 60. Roche Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 61. Roche Latest Developments
Table 62. Daiichi Sankyo Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 63. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Product Offered
Table 64. Daiichi Sankyo Main Business
Table 65. Daiichi Sankyo Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 66. Daiichi Sankyo Latest Developments
Table 67. Pfizer Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 68. Pfizer Duchenne Muscular Dystrophy Drugs Product Offered
Table 69. Pfizer Main Business
Table 70. Pfizer Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 71. Pfizer Latest Developments
Table 72. Cumberland Pharmaceuticals Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 73. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offered
Table 74. Cumberland Pharmaceuticals Main Business
Table 75. Cumberland Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 76. Cumberland Pharmaceuticals Latest Developments
Table 77. Santhera Pharmaceuticals Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 78. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offered
Table 79. Santhera Pharmaceuticals Main Business
Table 80. Santhera Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 81. Santhera Pharmaceuticals Latest Developments
Table 82. Taiho Pharmaceutical Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 83. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Product Offered
Table 84. Taiho Pharmaceutical Main Business
Table 85. Taiho Pharmaceutical Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 86. Taiho Pharmaceutical Latest Developments
Table 87. Teijin Pharma Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 88. Teijin Pharma Duchenne Muscular Dystrophy Drugs Product Offered
Table 89. Teijin Pharma Main Business
Table 90. Teijin Pharma Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 91. Teijin Pharma Latest Developments
Table 92. Akashi Therapeutics Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 93. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Product Offered
Table 94. Akashi Therapeutics Main Business
Table 95. Akashi Therapeutics Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 96. Akashi Therapeutics Latest Developments
Table 97. Sarepta Therapeutics Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 98. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Product Offered
Table 99. Sarepta Therapeutics Main Business
Table 100. Sarepta Therapeutics Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 101. Sarepta Therapeutics Latest Developments
Table 102. BioMarin Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 103. BioMarin Duchenne Muscular Dystrophy Drugs Product Offered
Table 104. BioMarin Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 105. BioMarin Main Business
Table 106. BioMarin Latest Developments
Table 107. Fibrogen Inc Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 108. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Product Offered
Table 109. Fibrogen Inc Main Business
Table 110. Fibrogen Inc Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 111. Fibrogen Inc Latest Developments
Table 112. Nobelpharma Co. Ltd Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 113. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Product Offered
Table 114. Nobelpharma Co. Ltd Main Business
Table 115. Nobelpharma Co. Ltd Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 116. Nobelpharma Co. Ltd Latest Developments
Table 117. Eloxx Pharmaceuticals Details, Company Type, Duchenne Muscular Dystrophy Drugs Area Served and Its Competitors
Table 118. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Product Offered
Table 119. Eloxx Pharmaceuticals Main Business
Table 120. Eloxx Pharmaceuticals Duchenne Muscular Dystrophy Drugs Revenue ($ million), Gross Margin and Market Share (2019-2024)
Table 121. Eloxx Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Duchenne Muscular Dystrophy Drugs Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Duchenne Muscular Dystrophy Drugs Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Duchenne Muscular Dystrophy Drugs Sales Market Share by Country/Region (2023)
Figure 8. Duchenne Muscular Dystrophy Drugs Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type in 2023
Figure 10. Duchenne Muscular Dystrophy Drugs in Hospitals
Figure 11. Global Duchenne Muscular Dystrophy Drugs Market: Hospitals (2019-2024) & ($ Millions)
Figure 12. Duchenne Muscular Dystrophy Drugs in Clinics
Figure 13. Global Duchenne Muscular Dystrophy Drugs Market: Clinics (2019-2024) & ($ Millions)
Figure 14. Duchenne Muscular Dystrophy Drugs in Others
Figure 15. Global Duchenne Muscular Dystrophy Drugs Market: Others (2019-2024) & ($ Millions)
Figure 16. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application in 2023
Figure 17. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Player in 2023
Figure 18. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Regions (2019-2024)
Figure 19. Americas Duchenne Muscular Dystrophy Drugs Market Size 2019-2024 ($ Millions)
Figure 20. APAC Duchenne Muscular Dystrophy Drugs Market Size 2019-2024 ($ Millions)
Figure 21. Europe Duchenne Muscular Dystrophy Drugs Market Size 2019-2024 ($ Millions)
Figure 22. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size 2019-2024 ($ Millions)
Figure 23. Americas Duchenne Muscular Dystrophy Drugs Value Market Share by Country in 2023
Figure 24. United States Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 25. Canada Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 26. Mexico Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 27. Brazil Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 28. APAC Duchenne Muscular Dystrophy Drugs Market Size Market Share by Region in 2023
Figure 29. APAC Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type in 2023
Figure 30. APAC Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application in 2023
Figure 31. China Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 32. Japan Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 33. Korea Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 34. Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 35. India Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 36. Australia Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 37. Europe Duchenne Muscular Dystrophy Drugs Market Size Market Share by Country in 2023
Figure 38. Europe Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
Figure 39. Europe Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2019-2024)
Figure 40. Germany Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 41. France Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 42. UK Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 43. Italy Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 44. Russia Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 45. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2019-2024)
Figure 48. Egypt Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 49. South Africa Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 50. Israel Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 51. Turkey Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 52. GCC Country Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 53. Americas Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 54. APAC Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 55. Europe Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 56. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 57. United States Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 58. Canada Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 59. Mexico Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 60. Brazil Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 61. China Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 62. Japan Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 63. Korea Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 64. Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 65. India Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 66. Australia Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 67. Germany Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 68. France Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 69. UK Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 70. Italy Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 71. Russia Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 72. Spain Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 73. Egypt Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 74. South Africa Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 75. Israel Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 76. Turkey Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 77. GCC Countries Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 78. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share Forecast by Type (2025-2030)
Figure 79. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share Forecast by Application (2025-2030)
Figure 1. Duchenne Muscular Dystrophy Drugs Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Duchenne Muscular Dystrophy Drugs Market Size Growth Rate 2019-2030 ($ Millions)
Figure 6. Duchenne Muscular Dystrophy Drugs Sales by Geographic Region (2019, 2023 & 2030) & ($ millions)
Figure 7. Duchenne Muscular Dystrophy Drugs Sales Market Share by Country/Region (2023)
Figure 8. Duchenne Muscular Dystrophy Drugs Sales Market Share by Country/Region (2019, 2023 & 2030)
Figure 9. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type in 2023
Figure 10. Duchenne Muscular Dystrophy Drugs in Hospitals
Figure 11. Global Duchenne Muscular Dystrophy Drugs Market: Hospitals (2019-2024) & ($ Millions)
Figure 12. Duchenne Muscular Dystrophy Drugs in Clinics
Figure 13. Global Duchenne Muscular Dystrophy Drugs Market: Clinics (2019-2024) & ($ Millions)
Figure 14. Duchenne Muscular Dystrophy Drugs in Others
Figure 15. Global Duchenne Muscular Dystrophy Drugs Market: Others (2019-2024) & ($ Millions)
Figure 16. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application in 2023
Figure 17. Global Duchenne Muscular Dystrophy Drugs Revenue Market Share by Player in 2023
Figure 18. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share by Regions (2019-2024)
Figure 19. Americas Duchenne Muscular Dystrophy Drugs Market Size 2019-2024 ($ Millions)
Figure 20. APAC Duchenne Muscular Dystrophy Drugs Market Size 2019-2024 ($ Millions)
Figure 21. Europe Duchenne Muscular Dystrophy Drugs Market Size 2019-2024 ($ Millions)
Figure 22. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size 2019-2024 ($ Millions)
Figure 23. Americas Duchenne Muscular Dystrophy Drugs Value Market Share by Country in 2023
Figure 24. United States Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 25. Canada Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 26. Mexico Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 27. Brazil Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 28. APAC Duchenne Muscular Dystrophy Drugs Market Size Market Share by Region in 2023
Figure 29. APAC Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type in 2023
Figure 30. APAC Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application in 2023
Figure 31. China Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 32. Japan Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 33. Korea Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 34. Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 35. India Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 36. Australia Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 37. Europe Duchenne Muscular Dystrophy Drugs Market Size Market Share by Country in 2023
Figure 38. Europe Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
Figure 39. Europe Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2019-2024)
Figure 40. Germany Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 41. France Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 42. UK Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 43. Italy Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 44. Russia Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 45. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size Market Share by Region (2019-2024)
Figure 46. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size Market Share by Type (2019-2024)
Figure 47. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size Market Share by Application (2019-2024)
Figure 48. Egypt Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 49. South Africa Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 50. Israel Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 51. Turkey Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 52. GCC Country Duchenne Muscular Dystrophy Drugs Market Size Growth 2019-2024 ($ Millions)
Figure 53. Americas Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 54. APAC Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 55. Europe Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 56. Middle East & Africa Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 57. United States Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 58. Canada Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 59. Mexico Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 60. Brazil Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 61. China Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 62. Japan Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 63. Korea Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 64. Southeast Asia Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 65. India Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 66. Australia Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 67. Germany Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 68. France Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 69. UK Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 70. Italy Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 71. Russia Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 72. Spain Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 73. Egypt Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 74. South Africa Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 75. Israel Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 76. Turkey Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 77. GCC Countries Duchenne Muscular Dystrophy Drugs Market Size 2025-2030 ($ Millions)
Figure 78. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share Forecast by Type (2025-2030)
Figure 79. Global Duchenne Muscular Dystrophy Drugs Market Size Market Share Forecast by Application (2025-2030)
